Q-omics provides the consensus-scored NYX profile across patient tissues and cancer cell-line models. NYX expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NYX is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, NYX RNA expression shows 9,111 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where NYX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NYX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NYX survival associations across molecular data types. NYX RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NYX RNA expression–survival associations across cancer types. High NYX expression shows unfavorable associations in MESO and LUSC, but favorable associations in KIRC, SCLC, OV and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for NYX RNA expression.
This table summarizes NYX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NYX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NYX shows lower tumor expression in KICH, THCA and COAD and higher tumor expression in BRCA, KIRC and LUSC. The KICH box plot shows higher NYX RNA expression in normal versus tumor tissue (log2 FC = −0.529, t-test p < 0.001).
This table shows molecular features associated with NYX in patient tissues and cancer cell lines. In patient samples, NYX shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NYX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
